Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
What an incredible time to own legal cannabis shares – particularly these shares.
Tilray Inc. (NASDAQ: TLRY) and Aurora Cannabis Inc. (OTC: ACBFF) have been the marijuana sector's "super stocks" of this summer. They've thrown off unthinkably large gains over the past few weeks and months.
Most recently, Tilray was riding high – up more than 30% – on news that it had secured U.S. Drug Enforcement Agency (DEA) approval to import research cannabis to the University of California San Diego's Center for Medicinal Cannabis Research.
And as you may have seen the other day, it's Aurora's turn for the spotlight…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
Will buy this stock!
Thx Michael Robinson. Is it good to buy this stock